IL156435A0 - Crystallization of igf-1 - Google Patents

Crystallization of igf-1

Info

Publication number
IL156435A0
IL156435A0 IL15643502A IL15643502A IL156435A0 IL 156435 A0 IL156435 A0 IL 156435A0 IL 15643502 A IL15643502 A IL 15643502A IL 15643502 A IL15643502 A IL 15643502A IL 156435 A0 IL156435 A0 IL 156435A0
Authority
IL
Israel
Prior art keywords
igf
crystallization
relates
candidate
indirect
Prior art date
Application number
IL15643502A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL156435A0 publication Critical patent/IL156435A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
IL15643502A 2001-02-09 2002-02-01 Crystallization of igf-1 IL156435A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26797701P 2001-02-09 2001-02-09
US28707201P 2001-04-27 2001-04-27
PCT/US2002/003156 WO2002064627A2 (en) 2001-02-09 2002-02-01 Crystallization of igf-1

Publications (1)

Publication Number Publication Date
IL156435A0 true IL156435A0 (en) 2004-01-04

Family

ID=26952796

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15643502A IL156435A0 (en) 2001-02-09 2002-02-01 Crystallization of igf-1
IL156435A IL156435A (en) 2001-02-09 2003-06-12 Formation of IGF-1

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL156435A IL156435A (en) 2001-02-09 2003-06-12 Formation of IGF-1

Country Status (19)

Country Link
US (8) US7084240B2 (enExample)
EP (3) EP1801120A1 (enExample)
JP (2) JP4489352B2 (enExample)
KR (1) KR100872613B1 (enExample)
CN (1) CN100439397C (enExample)
AT (2) ATE439378T1 (enExample)
AU (1) AU2002255508B2 (enExample)
BR (1) BR0207422A (enExample)
CA (1) CA2431033A1 (enExample)
DE (3) DE60217066D1 (enExample)
DK (2) DK1772464T3 (enExample)
ES (2) ES2278020T3 (enExample)
HU (1) HUP0500733A3 (enExample)
IL (2) IL156435A0 (enExample)
MX (1) MXPA03007042A (enExample)
NZ (3) NZ526672A (enExample)
PL (1) PL374181A1 (enExample)
WO (1) WO2002064627A2 (enExample)
ZA (1) ZA200304900B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1401476A4 (en) * 2001-03-14 2006-03-08 Genentech Inc IGF ANTAGONIST PEPTIDES
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
DE60224419D1 (de) * 2001-09-18 2008-02-14 Bioexpertise Llc Von igf-bindungsprotein stammendes peptid
US6914049B2 (en) * 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
CA2565308A1 (en) * 2003-05-06 2004-11-25 New Century Pharmaceuticals Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on their albumin binding properties
WO2005041895A2 (en) * 2003-11-03 2005-05-12 New Century Pharmaceuticals, Inc. Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on their albumin binding properties
ES2348303T3 (es) 2003-12-08 2010-12-02 Cpex Pharmaceuticals, Inc. Composiciones farmacauticas y procedimientos de tratamiento con insulina.
WO2005108424A1 (en) * 2004-05-06 2005-11-17 Genentech, Inc. Crystal structure of the complex of hepatocyte growth factor bata chain with met receptor and methods of use
US20060003931A1 (en) * 2004-05-06 2006-01-05 Genentech, Inc. Crystal structure of the hepatocyte growth factor and methods of use
WO2006014673A2 (en) * 2004-07-19 2006-02-09 Nobex Corporation Insulin-oligomer conjugates, formulations and uses thereof
WO2006039622A2 (en) * 2004-10-01 2006-04-13 Invitrogen Corporation Feeding buffers, systems, and methods for in vitro synthesis of biomolecules
US7556776B2 (en) * 2005-09-08 2009-07-07 President And Fellows Of Harvard College Microfluidic manipulation of fluids and reactions
US7994127B2 (en) * 2007-06-08 2011-08-09 Massachusetts Institute Of Technology Treatment of rett syndrome
WO2009026172A2 (en) * 2007-08-17 2009-02-26 The Regents Of The University Of California New approach for designing diabetes drugs
CN101139391B (zh) * 2007-08-21 2012-07-25 陈志南 Cd147胞外区晶体结构及应用
WO2009134395A2 (en) 2008-04-28 2009-11-05 President And Fellows Of Harvard College Microfluidic device for storage and well-defined arrangement of droplets
WO2011011071A2 (en) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1)
JP5571186B2 (ja) * 2009-07-22 2014-08-13 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ ５９位にアミノ酸置換を有するインスリン様増殖因子−１（ｉｇｆ−１）の類似体
WO2011047204A1 (en) * 2009-10-14 2011-04-21 Mount Sinai School Of Medicine Method of treating memory disorders and enhancing memory using igf-ii compounds
US20150119394A1 (en) * 2012-03-28 2015-04-30 Merck Sharp & Dohme Corp. Insulin-Like Growth Factor-1 Receptor Inhibitors
KR101711584B1 (ko) * 2012-12-18 2017-03-02 재단법인 의약바이오컨버젼스연구단 변형된 eprs 단백질의 결정 구조 및 이의 결정화 방법
US10279013B2 (en) 2013-12-19 2019-05-07 Puretein Bioscience Llc Methods for treating an animal
CA3153776A1 (en) 2019-09-09 2021-03-18 The University Of Chicago Combination therapy for the treatment of migraines
US20240050455A1 (en) * 2020-06-01 2024-02-15 Loma Linda University Health Methods of treatment of a cytokine storm

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US589867A (en) * 1897-09-14 Clothes-line hanger
US577276A (en) * 1897-02-16 Quarter-saver iv
US4672108A (en) * 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
WO1987001038A1 (en) * 1985-08-22 1987-02-26 Commonwealth Scientific And Industrial Research Or Peptide analogues of mammalian insulin-like growth factor-1
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
US4833233A (en) * 1987-08-20 1989-05-23 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Human serum albumin crystals and method of preparation
SE8703625D0 (sv) 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
US5470828A (en) * 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
US5164370A (en) * 1987-12-24 1992-11-17 Gropep Pty. Ltd. Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
EP0327503B1 (en) * 1988-02-05 1993-03-10 Ciba-Geigy Ag Use of igf i in the manufacture of a medicament for the treatment of renal diseases
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
GB8920381D0 (en) 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5028224A (en) * 1990-01-09 1991-07-02 Kimberly-Clark Corporation Apparatus for intermittently depositing particulate material in a substrate
US5681814A (en) 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
SE9100099D0 (sv) 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
DE69218948T2 (de) * 1991-08-01 1997-07-31 Auckland Uniservices Ltd IGF-I zur Verbesserung der neuronale Lage
US5126314A (en) * 1991-09-06 1992-06-30 Eastman Kodak Company Mixture of dyes for black dye donor for thermal color proofing
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
JPH07508025A (ja) 1992-05-08 1995-09-07 トーマス・ジェファーソン・ユニバーシティ インスリン様増殖因子（ｉｇｆ−１）類似体
SE9201573D0 (sv) 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
JPH08507916A (ja) 1992-06-09 1996-08-27 カイロン コーポレイション Ｍ−ｃｓｆの結晶化
DE69327402T2 (de) 1992-06-12 2000-05-04 Albert Einstein College Of Medicine Of Yeshiva University, Bronx Vorbeugung und behandlung der peripheren neuropathie
GB9217696D0 (en) 1992-08-20 1992-09-30 Agricultural & Food Res Use of specific binding molecules
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
JPH08500123A (ja) 1993-01-25 1996-01-09 ザ ベス イスラエル ホスピタル アソシエイション Ｉｇｆ−ｉ感受性細胞のバリヤー特性の修飾方法，診断方法及びスクリーニング方法
DK72793D0 (da) 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5534488A (en) * 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
US5407810A (en) 1993-08-20 1995-04-18 Genentech, Inc. Aqueous multiple-phase isolation of polypeptide
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
SE9402370D0 (sv) 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
SE9501472D0 (sv) 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I
DK0833847T3 (da) 1995-06-22 2003-12-29 Biogen Inc Krystaller af fregmenter af CD40-ligand og deres anvendelse
US5948751A (en) * 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
JP3417230B2 (ja) * 1996-09-25 2003-06-16 信越化学工業株式会社 型取り母型用光硬化性液状シリコーンゴム組成物
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
US5898028A (en) * 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
CA2294833A1 (en) 1997-07-03 1999-01-14 Smithkline Beecham Corporation Crystal structures of anti-factor ix fab fragments and methods of use for peptidomimetic design
US5876242A (en) * 1997-07-21 1999-03-02 Williams; Hugh D. Remote battery extension apparatus
NZ506091A (en) 1998-01-21 2003-07-25 Brigham & Womens Hospital Circulating insulin-like growth factor-i and prostate cancer risk
AU6515499A (en) 1998-10-16 2000-05-08 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
EP1383793B1 (en) 2000-03-29 2011-10-19 DGI BioTechnologies, L.L.C. Insulin and igf-1 receptor agonists and antagonists
WO2002098914A2 (en) 2001-06-07 2002-12-12 F. Hoffmann-La Roche Ag Mutants of igf binding proteins and methods of production of antagonists thereof
US20040137518A1 (en) * 2002-01-31 2004-07-15 Lambert Millard Hurst CRYSTALLIZED PPARa LIGAND BINDING DOMAIN POLYPEPTIDE AND SCREENING METHODS EMPLOYING SAME
JP3680801B2 (ja) * 2002-02-27 2005-08-10 株式会社デンソー 回転電機の巻線接合方法

Also Published As

Publication number Publication date
JP4489352B2 (ja) 2010-06-23
US20060287235A1 (en) 2006-12-21
WO2002064627A2 (en) 2002-08-22
US20060276397A1 (en) 2006-12-07
EP1358209B1 (en) 2006-12-27
US20060287510A1 (en) 2006-12-21
DK1772464T3 (da) 2009-12-14
BR0207422A (pt) 2005-04-19
NZ548358A (en) 2008-04-30
DE60217066T4 (de) 2010-07-01
MXPA03007042A (es) 2004-05-24
US20050215477A1 (en) 2005-09-29
US7238658B2 (en) 2007-07-03
US7084240B2 (en) 2006-08-01
US7297763B2 (en) 2007-11-20
WO2002064627A3 (en) 2003-07-31
AU2002255508B2 (en) 2008-04-03
NZ548359A (en) 2007-11-30
NZ526672A (en) 2006-10-27
US20060281905A1 (en) 2006-12-14
EP1801120A1 (en) 2007-06-27
DE60217066D1 (de) 2007-02-08
US20060270839A1 (en) 2006-11-30
DE60233359D1 (de) 2009-09-24
JP2009215299A (ja) 2009-09-24
ES2278020T3 (es) 2007-08-01
DK1358209T3 (da) 2007-05-07
CN1703425A (zh) 2005-11-30
EP1772464B1 (en) 2009-08-12
DE60217066T2 (de) 2007-07-12
ZA200304900B (en) 2005-07-27
CN100439397C (zh) 2008-12-03
ATE349469T1 (de) 2007-01-15
ATE439378T1 (de) 2009-08-15
US20060293507A1 (en) 2006-12-28
EP1772464A3 (en) 2007-10-03
IL156435A (en) 2009-09-22
JP2005503329A (ja) 2005-02-03
EP1358209A2 (en) 2003-11-05
ES2331150T3 (es) 2009-12-22
HK1060138A1 (en) 2004-07-30
US7433788B2 (en) 2008-10-07
US7596455B2 (en) 2009-09-29
PL374181A1 (en) 2005-10-03
CA2431033A1 (en) 2002-08-22
KR20040064610A (ko) 2004-07-19
HUP0500733A2 (hu) 2005-10-28
US7354769B2 (en) 2008-04-08
US20020165155A1 (en) 2002-11-07
KR100872613B1 (ko) 2008-12-09
HUP0500733A3 (en) 2010-01-28
EP1772464A2 (en) 2007-04-11

Similar Documents

Publication Publication Date Title
IL156435A0 (en) Crystallization of igf-1
PL362558A1 (en) Xylanase variants having altered sensitivity to xylanase inhibitors
WO2003040309A3 (en) Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
AR030504A1 (es) Peptidos ciclicos selectivos
DK1316801T3 (da) Sammensætninger og fremgangsmåder til detektion og behandling af sygdomme og tilstande, som er relateret til kemokinreceptorer
DE69918946D1 (de) Rezeptoren für il-18
MXPA04001730A (es) Metodo para determinacion de multiples analitos.
ITRM20020105A1 (it) Dispersione poliuretanica con elevata durezza della pellicola, procedimento per la sua preparazione e suo impiego.
WO2005117936A3 (en) Method for enhancing or inhibiting insulin-like growth factor-i
DK1363944T3 (da) Höjaffinitetsantagonister for ELR-CXC-kemokiner
WO2001040799A3 (en) Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias
SI1565490T1 (sl) Partnerji vezave holo transkobalaminov in njihovauporaba v kobalaminskem testu
DE69820483D1 (de) Antimicrobielles, mit getränken kompatibles schmiermittel für förderanlagen
WO2005103713A3 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
FI20031135L (fi) Jousikuormitettu kiilamainen pääteliitin, jossa on elementit yhteen kytkemiseksi ja johdinpitimen leukojen siirtymisen estämiseksi
WO2002102847A1 (fr) Nouveau ligand et son adn
DK0923644T3 (da) G-koblet receptor, der udviser selektiv selektivitet for ATP
WO2000003015A3 (en) Human transport protein homologs
WO2004070389A8 (en) Assay for protein isoforms
DE60226244D1 (de) Il-4 rezeptor sequenzvarianten, die mit typ i diabetes assoziiert sind
WO2003063769A3 (en) Vesicle-associated proteins
DE69929580D1 (de) Einfügungsmechanismus mit Kugelverriegelung, für Einschaltwiderstand
WO2001048483A3 (en) Method for screening of appetite control agents
AU2003239333A1 (en) The ligand binding pocket peptide fragment of estrogen-related receptor 3 (err3), its crystal structure, and uses thereof
AU3169599A (en) Method for screening substance promoting oligomerization of receptor protein molecules